Navigation Links
Vasomedical Announces Share Repurchase Program of up to $1.5 Million in Common Stock
Date:4/1/2013

WESTBURY, N.Y., April 1, 2013 /PRNewswire/ -- Vasomedical, Inc. (OTC BB: VASO), announced today that its Board of Directors has authorized a share repurchase program of up to $1.5 million of the Company's common stock. As of Friday, March 29, 2013, this would represent approximately 5% of the total outstanding shares of Vasomedical common stock.

"We have the capital resources available to implement a fairly aggressive stock repurchase program such as this, which amounts to roughly 5% of our total outstanding shares, and still invest in our company's business to drive future growth. We believe that our share price does not properly reflect the current value of our business or its potential future performance," said Dr. Jun Ma , President and Chief Executive Officer of Vasomedical, Inc. "We have a strong financial profile that gives us the flexibility to focus on our future plans to grow sales and achieve profitability, while supporting our stock. We believe this strategy shows our commitment to building shareholder value as well as confidence in achieving long-term growth."  

The share repurchase program is effective immediately. Repurchases will be made in accordance with applicable securities laws in the open market or in privately negotiated transactions. Depending on market conditions and other factors, these repurchases may be commenced or suspended from time to time without prior notice. The Company is under no obligation to fulfill the entire amount of the stock buyback program approved by the Board.

About Vasomedical
Vasomedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products.  The Company's main proprietary products are EECP® Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, Vasomedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; Vasomedical Global operates the Company's China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Additional information is available on the Company's website at www.vasomedical.com.

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipates", "believes", "could", "estimates", "expects", "may", "plans", "potential" and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250
tfromer@kcsa.com / grussell@kcsa.com  


'/>"/>
SOURCE Vasomedical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Vasomedical Announces Financial Results for the Fourth Quarter and Year Ended 2012
2. Vasomedical to Report Fourth Quarter and Year End 2012 Results on April 1, 2013
3. Vasomedical, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
4. Vasomedical, Inc. to Present Live Webcast at RetailInvestorConferences.com on February 7th
5. The International EECP Therapists Association and Vasomedical Announce Second Annual EECP Therapy Week
6. Vasomedical Common Stock Commences Trading on the OTCBB
7. Vasomedical Announces Financial Results for the Third Quarter of 2012
8. Vasomedical Named on Deloittes 2012 Technology Fast 500 List
9. Vasomedical Retains KCSA Strategic Communications as Corporate Communications Counsel
10. Bovie Medical Corporation Announces Fiscal Year 2012 Financial Results
11. Cardiac Science announces definitive agreement to sell its Diagnostic Cardiology product line to Mortara Instrument, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ROCKVILLE, Md. , Jan. 16, 2017 /PRNewswire/ ... tomography (CT) systems market is valued at $4.9 ... applications for CT, coupled with an aging population ... incidence of chronic disease, is propelling the market ... report, Computed Tomography Markets , focuses on ...
(Date:1/16/2017)... 2017 The report "Cellulose ... (Methyl, Ethyl, Hydroxyethyl, Hydroxypropyl, Carboxymethyl Cellulose), Application ... Coatings & Paints), Region - Global Forecast ... was valued at USD 4.51 Billion in ... 6.41 Billion by 2021, at a CAGR ...
(Date:1/16/2017)... , Jan. 16, 2017  Dovetail Genomics today ... sequencing and assembly service, which yields chromosome-scale genome assemblies. ... in a Dovetail-hosted workshop on Jan. 17 at the ... San Diego . "We are ... the launch of our Dovetail Hi-C offering," said ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... Specialty Technical Publishers (STP) ... Audit Protocol Consortium (IAPC) EHS audit protocol for Singapore . Leading companies ... their EHS regulatory obligations and rapidly collect, share, archive, and export audit findings ...
(Date:1/16/2017)... IL (PRWEB) , ... January 16, 2017 , ... ... (iaedp) organized to provide first-quality education and high-level training standards to an international ... spectrum of eating disorder problems. As a way to further its mission at ...
(Date:1/15/2017)... New York, NY (PRWEB) , ... January 15, 2017 , ... ... growing strategic accounts in the United States for the asthma & allergy friendly mark. ... of America to independently test and identify consumer products to be more suitable for ...
(Date:1/15/2017)... ... January 15, 2017 , ... San Francisco Magazine recently queried ... counties for 2017. Almost 1,000 nominations were submitted and a little over 500 ... were announced the magazine’s January 2017 issue . , Under the category ...
(Date:1/14/2017)... ... January 13, 2017 , ... According to ... magnesium-rich Mediterranean diet may lower the risk of type 2 diabetes, Alzheimer’s, and ... many health and wellness benefits linked to a Mediterranean diet are only some ...
Breaking Medicine News(10 mins):